XTL Biopharmaceuticals Ltd. (XTLB) Financials

XTLB Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 2.7 million 162000
June 30, 2023 2.9 million 163000
March 31, 2023 3.3 million 241000
Dec. 31, 2022 4.2 million 187000

XTLB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 ? ?
June 30, 2023 ? ?
March 31, 2023 ? ?
Dec. 31, 2022 -2.0 million 14000

XTLB Net Income

No data available :(

XTLB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 2.2 million - -
June 30, 2023 2.4 million - -
March 31, 2023 2.9 million - -
Dec. 31, 2022 3.7 million - -

XTLB Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 544.9 million
June 30, 2023 544.9 million
March 31, 2023 544.9 million
Dec. 31, 2022 544.9 million

XTLB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 - 6000 145000 -
June 30, 2023 - 6000 157000 -
March 31, 2023 - 13000 238000 -
Dec. 31, 2022 - 6000 219000 -

XTLB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - -
June 30, 2023 - -
March 31, 2023 - -
Dec. 31, 2022 -459000 -

XTLB

Price: $2.82

52 week price:
2.01
10.28

Earnings Per Share: -0.90 USD

P/E Ratio: -0.90

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 5727

Ebitda: -1.4 million

Market Capitalization: 6.4 million

Links: